Dr Brenda Finney discusses the possibility of utilising all of your existing and new data for effective drug discovery and development.
Author archives: Glenn Myatt
(Q)SAR and veterinary medicinal products
(Q) SAR and veterinary medical products
Society of Toxicology 2023 Meeting
Instem’s In Silico summary for SOT 2023.
Polo-like kinase 4 (PLK4) safety review – distilling the risks with a rapid augmented intelligence approach (Guest Author Dr Frances Hall)
Guest Author Dr Frances Hall highlights the risks with the augmented intelligence approach when providing a safety review for PLK4.
Assessing carcinogenicity risk of nitrosamines and supporting the ICH S1B guideline
At this year’s SOT in Nashville (March 19-23, 2023), Instem will be organizing two workshops related to cancer assessments.1 In the first workshop, to be held on Tuesday, March 21, 4:30 PM – 5:30 PM (CT) in Room 101B, we will discuss carcinogenicity assessments aligned with the ICH S1B guideline2, specifically focusing on the weight …
Nine Instem Posters at the 2023 SOT Meeting
Instem will again have a large presence at this year’s Society of Toxicology meeting in Nashville.1 As part of the scientific program, we will be co-authoring on nine posters covering the spectrum of scientific topics where we are undertaking research and development activities. This work supports many regulatory mandates and guidelines, including SEND, carcinogenicity risk …
Continue reading “Nine Instem Posters at the 2023 SOT Meeting”
Final meeting of the current eTRANSAFE consortium
The eTRANSAFE project1 is a strategically important project that has been developing a translational technology infrastructure to support drug safety assessments. The project started around 5 years ago and has been jointly funded by the European Innovative Medicines Initiative alongside the pharmaceutical industry. The partners on the project include representatives from the pharmaceutical industry, academia, …
Continue reading “Final meeting of the current eTRANSAFE consortium”
FDA Modernization Act 2.0
The U.S. Congress recently passed the FDA Modernization Act 2.01 which permits the use of alternatives to animal studies as part of the FDA’s regulatory approval process. The new legislation explicitly identifies in silico models as one of these alternatives. This legislation is an important step forward in the use of alternative methods and will …
The Use of Artificial Intelligence to Support Safety Predictions
Last year, we were happy to contribute to a new book describing the use of both supervised and unsupervised machine learning approaches to support the prediction of toxicity and is illustrated with case studies related to regulatory submissions. The book chapter emphasized the importance of high-quality databases, containing toxicology and chemistry information. Such comprehensive databases …
Continue reading “The Use of Artificial Intelligence to Support Safety Predictions”
Computational toxicology 2022 year-end review
The computational toxicology group here at Instem has had another busy year that has resulted in six publications and book chapters1-6, completion of existing and initiation of new collaborative working groups, as well as significant updates to our computational toxicology solutions. We have been collaborating on a number of research topics related to the in …
Continue reading “Computational toxicology 2022 year-end review”